Price
$20.31
Increased by +1.10%
Dollar volume (20D)
24.95 M
ADR%
1.66
Earnings report date
Feb 12, 2025
Shares float
62.84 M
Shares short
2.02 M [3.22%]
Shares outstanding
635.24 M
Market cap
13.28 B
Beta
0.86
Price/earnings
19.70
20D range
19.85 22.33
50D range
19.85 23.75
200D range
19.85 31.88

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.

In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease.

It operates various active pre-clinical programs.

The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.

It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S.

Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 6, 24 0.29
Decreased by -38.30%
0.35
Decreased by -17.14%
Aug 8, 24 0.31
Increased by +3.33%
0.33
Decreased by -6.06%
May 2, 24 0.29
Increased by +480.00%
0.14
Increased by +107.14%
Feb 14, 24 0.14
Increased by +16.67%
3.99
Decreased by -96.49%
Nov 7, 23 0.47
Decreased by -11.32%
3.14
Decreased by -85.03%
Aug 3, 23 0.30
Decreased by -26.83%
2.18
Decreased by -86.24%
May 10, 23 0.05
Decreased by -54.55%
0.65
Decreased by -92.31%
Feb 22, 23 0.12
Decreased by -29.41%
3.15
Decreased by -96.19%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 5.54 B
Increased by +16.78%
1.27 B
Decreased by -40.54%
Increased by +22.85%
Decreased by -49.08%
Jun 30, 24 5.40 B
Increased by +28.68%
1.41 B
Increased by +3.76%
Increased by +26.06%
Decreased by -19.37%
Mar 31, 24 4.14 B
Increased by +45.16%
1.32 B
Increased by +530.95%
Increased by +31.98%
Increased by +334.65%
Dec 31, 23 4.68 B
Decreased by -10.50%
640.00 M
Increased by +9.59%
Increased by +13.68%
Increased by +22.45%
Sep 30, 23 4.74 B
Increased by +16.08%
2.13 B
Decreased by -17.54%
Increased by +44.88%
Decreased by -28.96%
Jun 30, 23 4.20 B
Increased by +32.76%
1.36 B
Decreased by -28.24%
Increased by +32.32%
Decreased by -45.95%
Mar 31, 23 2.85 B
Increased by +34.69%
210.00 M
Decreased by -54.84%
Increased by +7.36%
Decreased by -66.47%
Dec 31, 22 5.23 B
Increased by +99.58%
584.00 M
Decreased by -18.44%
Increased by +11.17%
Decreased by -59.13%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY